1
|
Delgado-Balderas JR, Gallardo-Blanco HL, Yee-De León JF, Rivas-Estilla AM, Soto-García B, Aráiz-Hernández D, Garza-Guajardo R, Náñez-Marín M, Hernández-Barajas D, García-Bailón AM, Vízcarra-Mata G, Ocaña-Munguía MA, Gómez-Guerra LS, Sánchez-Domínguez CN. Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer. Oncol Lett 2020; 20:261. [PMID: 32989395 PMCID: PMC7517572 DOI: 10.3892/ol.2020.12124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Accepted: 07/31/2020] [Indexed: 11/25/2022] Open
Abstract
The presence of the genetic variants of the steroid 5-alpha reductase 2 enzyme, which is encoded by the SRD5A2 gene, has been associated with an increased risk of developing prostate cancer among certain ethnic groups. However, these molecular studies have not been conducted on the Mexican population. The analysis of the genetic variants, rs9282858 and rs523349, was performed in 101 males with prostate cancer and 100 healthy controls classified as males without prostate abnormalities (n=60) and males with benign prostatic hyperplasia (n=40), to identify a probable association with this cancer type in the Northeast Mexican population. An association was identified between prostate cancer and biomass exposure [P=0.012; odds ratio (OR), 2.89; confidence interval (CI)=1.21-6.88] and tobacco use (P=0.028; OR=1.88; CI=1.07-3.31), while no association was observed between cancer development and the rs9282858 variant, or between a protective effect and the rs523349 variant. Notably, an association was identified between rs523349 and biomass exposure (P=0.013, OR=3.17; CI=1.23-8.17 for the G risk allele, and OR=0.32, CI=0.12-0.81 for the C protective allele) using the dominant genetic model. To the best of our knowledge, the present study was the first of its type to investigate the Mexican population with prostate cancer.
Collapse
Affiliation(s)
- Jesus Rolando Delgado-Balderas
- Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | | | | | - Ana Maria Rivas-Estilla
- Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | | | | | - Raquel Garza-Guajardo
- Pathological Anatomy and Cytopathology Service, 'Dr. José Eleuterio González' University Hospital, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | - Melissa Náñez-Marín
- Pathological Anatomy and Cytopathology Service, 'Dr. José Eleuterio González' University Hospital, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | - David Hernández-Barajas
- Oncology Service, University Center Against Cancer, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | - Aldo Missael García-Bailón
- Urology Service, 'Dr. José Eleuterio González' University Hospital, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | - Guillermo Vízcarra-Mata
- Urology Service, 'Dr. José Eleuterio González' University Hospital, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | - Marco Alberto Ocaña-Munguía
- Urology Service, 'Dr. José Eleuterio González' University Hospital, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | - Lauro Salvador Gómez-Guerra
- Urology Service, 'Dr. José Eleuterio González' University Hospital, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| | - Celia Nohemí Sánchez-Domínguez
- Department of Biochemistry and Molecular Medicine, School of Medicine, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
| |
Collapse
|